Related trials
Buse, 2011 - exenatide vs placebo add on insulin
Lewin, 2010 - linagliptin vs placebo (add on to sulphonylurea)
DURATION-2 (Bergenstal) (vs sitagliptin), 2010 - exenatide vs sitagliptin
DURATION-3 (Diamant), 2010 - exenatide vs insulin glargine
Ratner DRI6012, 2010 - lixisenatide vs placebo add on MET
DURATION-2 (Bergenstal) (vs pioglitazone), 2010 - exenatide vs pioglitazone
Goodman, 2009 - vildagliptin vs placebo (add on to metformin)
HOME, 2009 - metformin vs placebo
LEAD-2 (Nauck) (vs placebo), 2009 - liraglutide vs placebo add on MET
Nauck (Sulf vs pbo), 2009 - vs placebo
9607, 2009 - exenatide vs placebo add on MET+/-SU
Li, 2009 - nateglinide vs repaglinide
LEAD-2 (vs MET), 2009 - liraglutide vs metformin
Ferrannini, 2009 - vildagliptin vs Sulfonylurea (add on to metformin)
LEAD-3 mono (Garber), 2009 - liraglutide vs glimepiride
Kaku, 2009 - mitiglinide vs placebo (on top pioglitazone )
COSMIC, 2009 - vs
LEAD-2 (Nauck) (vs glimepiride), 2009 - liraglutide vs glimepiride add on MET
DeFronzo, 2009 - saxagliptin vs placebo (add on to metformin)
RECORD, 2009 - rosiglitazone vs standard glucose-lowering drugs
Nauck, 2009 - alogliptin vs placebo (add on to metformin)
Nauck (vs GLP-1 analog), 2009 - vs GLP-1 analog
Filozof, 2009 - vildagliptin as add-on therapy vs gliclazide
Bolli, 2008 - vildagliptin vs pioglitazone (on top of metformin)
Moretto, 2008 - exenatide vs placebo
See also:
All test diab�te clinical trials
All diabetes clinical trials
All type 2 diabetes - sanofi clinical trials
All clinical trials of insulin secretagogues peptides (incretins)
All clinical trials of liraglutide
|
|
Treatments
Studied treatment |
Liraglutide 1.8 mg daily
|
Control treatment |
Glargine on-top of sulphonylureas+metformin
|
Concomittant treatment |
sulphonylureas+/-metformin |
Patients
Baseline characteristics |
Age (year) |
57 |
Duration of diabetes (year) |
9.4 y |
HbA1c (%) |
8.2 |
BMI |
30.5 |
Add-on to |
SU+/-Met |
|
Method and design
Randomized effectives |
230 / 232 (studied vs. control) |
Blinding |
not reported |
Follow-up duration |
26 weeks |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
nausea
32 / 230
3 / 232
classic
10,76 [3,34;34,64]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
nausea
|
32 / 230 (13,9%) |
3 / 232 (1,3%) |
10,76 |
[3,34;34,64] |
|
0 |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
nausea |
13,91% |
1,29% |
12,6%
|
Meta-analysis of all similar trials:
antidiabetic drugs in test diab�te for type 2 daibetes (NIDD)
insulin secretagogues peptides (incretins) in diabetes for all type of patients
insulin secretagogues peptides (incretins) in type 2 diabetes - sanofi for all type of patients
Reference(s)
-
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim� R, , .
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial..
Diabetologia 2009;52:2046-55.
- 10.1007/s00125-009-1472-y
Pubmed
|
Hubmed
| Fulltext
-
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim� R.
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial..
Diabetologia 2009 Oct;52:2046-55
Pubmed
|
Hubmed
| Fulltext
-
Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone..
Cardiovasc Diabetol 2009 Feb 26;8:12
Pubmed
|
Hubmed
| Fulltext
|